Several enzymes involved in the biosynthesis of nucleic acid precursors have become attractive biochemical target sites over the past twenty years. In particular, dihydrofolate reductase (DHFR), a crucial NADPH-linked dehydrogenase that catalyses the reduction of dihydrofolate (and folate with a lower efficiency) to tetrahydrofolate has attracted considerable attention.
Several enzymes involved in the biosynthesis of nucleic acid precursors have become attractive biochemical target sites over the past twenty years. In particular, dihydrofolate reductase (DHFR), a crucial NADPH-linked dehydrogenase that catalyses the reduction of dihydrofolate (and folate with a lower efficiency) to tetrahydrofolate has attracted considerable attention.
1) The inhibition of this ubiquitous enzyme, which plays an essential role in maintaining cellular pools of tetrahydrofolate derivatives, has led to major drugs for use in cancer chemotherapy and as antiprotozoan and antibacterial agents.
2) These compounds are conventionally divided into two main classes : "classical" antifolates bearing a glutamate moiety (also present in the natural folic substrate) and "nonclassical" antifolates devoid of this side-chain, which confer a rather lipophilic character to such molecules. The prominent example of "classical" DHFR inhibitors is methotrexate (MTX, 1) which is a potent and still widely employed antineoplastic agent, 3) whereas "non-classical" antimetabolites, such as trimethoprim (TMP, 2), trimetrexate (TMQ, 3), piritrexim (PTX, 4) and pyrimethamine (PM, 5) are more particularly used against pathogenic microorganisms. In this context, during the last decade, a renewed interest in this area appeared because of the persistent demand for novel drugs for treatment and prophylaxis of opportunistic infections in immunosuppressed AIDS victims. 4) As an application of the synthetic strategy to the 6-arylfuro [2,3-d] pyrimidine system that we developed a few years ago, 5) we describe herein the preparation and biological evaluation of several conformationally constrained analogues of 2. The new potential folate antagonists prepared in the present work are related to several other 6/5-fused heterocyclic systems including cyclopenta [d] 10) and furo [2,3-d] pyrimidines; 11) but midin-4-(3H)-ones (8a-s and 9a-t) were generally synthesized from 2-amino-4,6-dihydroxypyrimidine (6) and the corresponding 2-chloro-2-nitroethenylbenzenes (7). Compounds 8a-s were prepared, at room temperature, in a mixture of ethanol-butanone in the presence of triethylamine, whereas furo[2,3-d]pyrimidines 9a-t were obtained in a refluxing mixture of ethanol and butanone in the presence of 1, 8-diazabicyclo[5.4 .0]undec-7-ene (DBU). The novel 3,4,5-trimethoxyphenyl derivatives (10) (11) (12) (13) (14) , related to the TMP model (2), were prepared, as shown in Chart 2, starting from 2-amino-5-(3,4,5-trimethoxyphenyl)-furo [2,3-d] pyrimidin-4-(3H)-one (9e). Direct catalytic hydrogenation of 9e gave 2-amino- 5,6-dihydro-5-(3,4,5-trimethoxyphenyl) furo [2,3-d] pyrimidin-4-(3H)-one (10) . Chlorination of 9e with phosphorous oxychloride in the presence of diethylaniline hydrochloride provided 2-amino-4-chloro -5-(3,4,5-trimethoxyphenyl) furo [2,3-d] pyrimidin-4-(3H)-one (11) which was further converted into 2,4-diamino -5-(3,4,5-trimethoxyphenyl) furo [2,3-d] pyrimidine (12) by heating for five days in an autoclave with ammonia in methanol. Catalytic reduction of 12 in dioxane gave either 2,4-diamino- 5,6-dihydro-5-(3,4,5-trimethoxyphenyl) furo [2,3-d] pyrimidine [13 (by using 5% Pd-C)] or 6-hydroxy-5-[1-(3,4,5-trimethoxyphenyl)-1-ethyl]-2,4-pyrimidinediamine [14 (by using 10% Pd-C)]. A plausible mechanism to explain the a priori unexpected opening of the furan ring leading to the formation of 14 is detailed in Chart 3. In the same context, because of the similar substitution of the side-aromatic ring with that of the "non classical" antifolate PTX (4), 2-amino-5,6-dihydro-5-(2,5-dimethoxyphenyl)furo [2,3-d] pyrimidin-4-(3H)-one (15) was also prepared by catalytic hydrogenation of 2-amino-5-(2,5-dimethoxyphenyl)furo [2,3-d] pyrimidin-4-(3H)-one (9p), as depicted in Chart 4.
Diethyl N- [4-(2-amino-4(3H)-oxofuro[2,3-d] pyrimidin-5-yl)benzoyl]-L-glutamate (17) was synthesized in good yield by condensation of 16 with diethyl L-glutamate in the presence of N-methylmorpholine (NMM) and triazine in anhydrous dimethylformamide (DMF) at room temperature. 4-(2-Amino-4(3H)-oxofuro[2,3-d]pyrimidin-5-yl)benzoic acid (16) was obtained by hydrolysis of the corresponding methyl ester (9t). Further transformations of this ester 17 gave N- [4-(2-amino-4 glutamic acid (18) [by alkaline hydrolysis followed by acidification] or diethyl N- [4-(2-amino-5,6-dihydro-4 (20) was then prepared either by hydrogenation of 18 or by hydrolysis of 19 in comparable overall yields based on 17 (Chart 5).
Biological Results
Along with TMP (2), the compounds synthesized in the present study were evaluated as inhibitors of DHFR from different species ( Tables 1-3, respectively. In order to summarize these Tables, we have chosen to mention only those products exhibiting a significant activity (i.e. IC 50 Ͻ300 mM for at least one of the tested DHFR, minimum inhibitory concentrations value (MIC)Յ 64 mg/ml for at least one of the tested strains in the antibacterial assays, and IC 50 Ͻ5 mg/ml for the antimalarial evaluation).
The results reported in Table 1 deal with enzyme inhibition and show that several, of the evaluated compounds exhibited a moderate IC 50 (Ͻ30 mM), but only a few have a strong IC 50 (Ͻ10 mM, which is the threshold usually required to expect activity in the corresponding species). However, it is worth pointing out that, in several cases, for a given compound (e.g. 8d, 8h, 8l, 8r, 9b, 9c, 9p, 9r, 10, 11, 12, 13 or 15), significant differences in inhibition were observed between the examined enzymes. The selectivity for the human enzyme was generally poor but, in many cases, inhibition of the human enzyme was more pronounced than that of bacterial or P. carinii enzymes. This was especially observed with derivatives 17, 18, 19 and 20 bearing a L-glutamic side chain. Nevertheless, activities in this series remain much lower than those determined for MTX (1) which exhibits an IC 50 of about 0.004 mM against recombinant human DHFR. 11b,c) From the MICs gathered in Table 2 , it appears that only seven compounds (8a, 9a, 9d, 9l, 9o, 9s and 15) showed slight activity against some strains (MICs between 16 and 64 mg/ml). Most active compounds contained mono-substituted phenyl substituents, whereas compounds with multiplesubstituted phenyls were inactive. Substances with in vitro activity had relatively low IC 50 values against the corresponding enzyme, although the converse was not true. Factors such as permeability and intracellular accumulation must also play a role. The marginal activity observed both in the enzyme and in vitro tests is too weak for any certain correlation between DHFR inhibition and antibacterial activity. The fact that antibacterial activity was not always observed against the strains most sensitive to TMP (2) suggests some differences in the mode of binding to DHFR. a) The symbol (Ͼ) indicates that the MIC was not reached at the highest concentration tested. The symbol (Յ) indicates that the MIC was lower or equal to the reported concentrations.
The IC 50 summarized in Table 3 indicate that three compounds, 8c, 9b and especially 15, exhibited slight activity in the in vitro test against P. falciparum. The common structural feature of these compounds is a methoxy-substituted phenyl substituent. The compounds were equally active against pyrimethamine-resistant (K1) and sensitive (NF 54) strains , suggesting a different mode of binding to DHFR, or another mode of action.
Experimental
Melting points were measured on a Köfler hot stage apparatus and are uncorrected. Mass spectra were obtained with a Nermag-Ribermag R10-10C spectrometer applying a desorption chemical ionization (CI) technique using ammonia as the reagent gas or an electrospray ionization (ESI) method. Infrared spectra were obtained with a Perkin-Elmer 1710 spectrophotometer for chloroform solutions or KBr discs. The 1 H-NMR (90 and 300 MHz) spectra were recorded on Varian EM 390 and Bruker AC 300 spectrometers, respectively. Chemical shifts are expressed as parts per million downfield from tetramethylsilane. Splitting patterns are designated as follows: s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quadruplet), m (multiplet), br (broad signal) and sh (shoulder). Coupling constants (J values) are listed in hertz (Hz). Reactions were monitored by analytical thin layer chromatography and products were visualized by exposure to UV light. Merck silica gel (230-400 mesh ASTM) was used for column chromatography. Methanol and CH 2 Cl 2 employed as eluents were distilled on a rotary evaporator prior to use. Anhydrous triethylamine was obtained by distillation from calcium hydride. Dry tetrahydrofuran (THF) was prepared by distillation from benzophenone/sodium. Commercial anhydrous ethanol and butanone were used without further purification. Starting 2-amino-4,6-dihydroxypyrimidine (6), reagents, and palladium 10% catalyst were purchased from Aldrich Chemical Co. Palladium 5% on activated carbon was obtained from Strem Chemicals Inc. Large quantities of the required Z-(2-chloro-2-nitroethenyl)benzenes 7a-t were prepared according to our previously reported procedure. 12, 13) Compounds 7a-j 12) and 7k-o 13) have already been described. The new b-chloro-b-nitrostyrenes 7p-t were especially synthesized on a 0.2 mole scale for the present work.
Z-(2-Chloro-2-nitroethenyl)-2,5-dimethoxybenzene (7p) Yield 79% (38.5 g), mp 89-90°C (recrystallized from heptane , 3.33; N, 5.79. Found: C, 49.53; H, 3.37; N, 5.76 . The starting methyl 4-formylbenzoate (mp 60-62°C recrystallized from pentane) was easily prepared in 95% yield by adding thionyl chloride dropwise, at room temperature, to a mixture of 4-formylbenzoic acid and methanol.
2-Amino-5,6-dihydro-6-nitro-5-phenylfuro[2,3-d]pyrimidin-4(3H)-one (8a)
A solution of Z-(2-chloro-2-nitroethenyl)benzene (7a) (918 mg, 5 mmol) in a mixture of anhydrous ethanol (33 ml) and butanone (17 ml) was placed in a dried, two-necked, 100 ml round-bottomed flask fitted with a septum inlet. 2-Amino-4,6-dihydroxypyrimidine (6) (690 mg, 5.5 mmol) was then added in one portion under argon atmosphere. Dry triethylamine (2.53 g, 3.5 ml, 25 mmol) was introduced via a syringe and the mixture was efficiently stirred for five days. The reaction mixture was suction-filtered through a short pad of Celite. The Celite was thoroughly rinsed with a CH 2 Cl 2 /methanol 9/1 mixture and the combined volatile materials were evaporated under reduced pressure. The crude product was chromatographed over a silica gel column (300 g, eluent CH 2 Cl 2 /methanol: 9/1). Removal of the solvent followed by subsequent recrystallisation in a mixture water/ethanol afforded pure 8a in 60% yield (822 mg), mp Ͼ260°C. 2-Amino-5-aryl-5,6-dihydro-6-nitrofuro[2,3-d]pyrimidin-4(3H)-ones 8b-s were synthesized from 7b-s in a manner similar to that described above for the preparation of 8a. 
2-Amino-5,6-dihydro-5-(2-methoxyphenyl)-6-nitrofuro[2,3-d]pyrimidin-4(3H)-one (8b)

2-Amino-5-phenylfuro[2,3-d]pyrimidin-4(3H)-one (9a)
A solution of Z-(2-chloro-2-nitroethenyl)benzene (7a) (918 mg, 5 mmol) in a mixture of anhydrous ethanol (33 ml) and butanone (17 ml) was placed in a dried, twonecked, 100 ml round-bottomed flask fitted with a septum inlet and a water condenser. 2-Amino-4,6-dihydroxypyrimidine (6) (690 mg, 5.5 mmol) was then added in one portion under an argon atmosphere. The mixture was stirred at room temperature for ten minutes and DBU (3.80 g, 3.74 ml, 25 mmol) was introduced via a syringe. The reaction mixture was smoothly refluxed, with stirring, using an oil bath. When the starting material 7a had completely disappeared as judged by thin layer chromatography (eluent CH 2 Cl 2 /methanol: 9/1), three hours in this case, the mixture was allowed to cool to room temperature and filtered by suction through a short pad of Celite. The Celite was thoroughly rinsed with a CH 2 Cl 2 /methanol 9/1 mixture and the combined volatile materials were evaporated in vacuo. The crude product was chromatographed over a silica gel column (300 g, eluent CH 2 Cl 2 /methanol: 9/1). Removal of the solvent followed by washing of the obtained solid in boiling ethanol gave satisfactorily pure 9a in 61% yield (693 mg), mp Ͼ260°C. The 2-amino-5-arylfuro[2,3-d]pyrimidin-4(3H)-ones 9b-t were synthesized from 7b-t in a manner similar to that described above for the preparation of 9a. When the reaction time or the employed solvent was different of those used for 9a, they are especially mentioned. -5-(3-chlorophenyl)furo[2,3-d]pyrimidin-4(3H)-one (9g (9e) (32 mg, 0.1 mmol) in dioxane (7 ml) was stirred for 16 h under hydrogen in the presence of 5% Pd-C (12 mg) at atmospheric pressure and at room temperature. After filtration through a pad of Celite, the filtrate was evaporated in vacuo. The obtained residue was further chromatographed over a silica gel column (10g, eluent CH 2 Cl 2 / methanol: 93/7) to give the desired compound 10 in 90% yield (29 mg , 5.37; N, 13.16. Found: C, 56.71; H, 5.19; N, 13.23 .
2-Amino-5-(2-methoxyphenyl)furo[2,3-d]pyrimidin-4(3H)-one (9b)
2-Amino
2-Amino-4-chloro-5-(3,4,5-trimethoxyphenyl)furo[2,3-d]pyrimidine (11)
Diethylaniline hydrochloride (315 mg, 1.7 mmol) and freshly distilled phosphorus oxychloride (7.5 g, 12.3 ml, 80 mmol) were successively added to 9e (317 mg, 1 mmol). The mixture was heated overnight at 60°C under an argon atmosphere using an oil bath. After cooling, the excess POCl 3 was evaporated under reduced pressure. The residue was taken up with CH 2 Cl 2 (25 ml) and crushed ice (25 g). The whole was stirred at room temperature for 1 h. After decantation, the aqueous layer was extracted with CH 2 Cl 2 (3ϫ25 ml). The combined organic phases were then successively washed with 1 N hydrochloric acid (15 ml), aqueous saturated NaHCO 3 (2ϫ10 ml), and ice-water (2ϫ20 ml). After drying (MgSO 4 ), filtration, and removal of the solvent in vacuo, the residue was flash-chromatographed over a silica gel column (60g, eluent CH 2 Cl 2 /methanol : 96/4) to give the desired compound 11 in 74% yield (248 mg), mp 247-249°C (recrystallized from ethanol 15 H 14 C l N 3 O 4 : C, 53.66; H, 4.20; N, 12.52. Found: C, 53.45; H, 4.11; N, 12.79 .
2,4-Diamino-5-(3,4,5-trimethoxyphenyl)furo[2,3-d]pyrimidine (12)
A solution of the chloro derivative 11 (168 mg, 0.5 mmol) in saturated methanolic ammonia (10 ml) was heated in a stainless steel bomb at 100°C for 5 days using an oil bath. Ammonia and methanol were evaporated under reduced pressure. The residue was then purified by silica gel chromatography (60 g, eluent CH 2 Cl 2 /methanol : 85/15) to provide the diamino derivative 12 in 65% yield (103 mg C, 56.96; H, 5.10; N, 17.71. Found: C, 56.73; H, 4.93; N, 17.99. 2,4-Diamino-5,6-dihydro-5-(3,4,5-trimethoxyphenyl)furo[2,3-d]pyrimidine (13) The 5,6-dihydro derivative 13 was prepared starting from 12 (32 mg, 0.1 mmol) by a procedure similar to that described for 10 in 90% yield (29 mg C, 56.60; H, 5.70; N, 17.60. Found: C, 56.35; H, 5.81; N, 17.65 .
6-Hydroxy-5-[1-(3,4,5-trimethoxyphenyl)-1-ethyl]-2,4-pyrimidinediamine (14)
The pyrimidinediamine 14 was obtained in 68% yield (28 mg) starting from 12 (32 mg, 0.1 mmol) in a similar manner to that employed for 10, but using 10% Pd-C (12 mg) instead of 5% Pd-C (in this case, a trace of 13 was also detected by TLC), mp 259-260°C. , 5.23; N, 14.53. Found: C, 58.35; H, 5.13; N, 14.63. 4-(2-Amino-4(3H)-oxofuro[2,3-d]pyrimidine-5-yl)benzoic acid (16) The ester 9t (285 mg, 1 mmol) was suspended in aqueous 1 N sodium hydroxide (4 ml) and the mixture was stirred at room temperature. The solid disappeared gradually and the solution obtained after 3 h was acidified with acetic acid (0.8 ml). The formed precipitate was suction-filtered and successively washed with water (3 ml) and diethyl ether (3 ml) to afford satisfactorily pure 16 in 73% yield (178 mg (10 ml) . This mixture was stirred at room temperature for 2 h before 4-chloro-4,6-dimethoxytriazine (110 mg, 0.63 mmol) and N-methylmorpholine (151 mg, 0.165 ml, 1.5 mmol) were added again (this two-fold addition process provided better yields than the direct use of reagents in excess). The solution was stirred for 30 additional minutes and N-methylmorpholine (322 mg, 0.35 ml, 3.18 mmol), then diethyl L-glutamate hydrochloride (0.76 g, 3.5 mmol) were successively added. The reaction mixture was stirred at room temperature for 16 h and silica gel (3 g) was added. The suspension was evaporated to dryness under reduced pressure. The obtained residue was loaded on a dry silica gel column (60 g) and eluted with a mixture CH 2 Cl 2 /methanol : 94/6. The fractions corresponding to the product were pooled, then evaporated in vacuo to give satisfactorily pure 17 in 90% yield (1.30 g), mp Ͼ260°C. , 5.30; N, 12.27. Found: C, 57.51; H, 5.19; N, 12.63 .
N-[4-(2-Amino-4(3H)-oxofuro[2,3-d]pyrimidin-5-yl)benzoyl]-L-glutamic acid (18)
The above diester 17 (46 mg, 0.1 mmol) was suspended in aqueous 1 N sodium hydroxide (3 ml) and the mixture was stirred at room temperature. The solid disappeared gradually and the solution obtained after 3 h was acidified with acetic acid (0.7 ml). The measured pH (test paper) was about 3. The precipitate that formed was collected by filtration and was thoroughly washed with water (4 ml) and diethyl ether (3 ml) to afford, after drying in vacuo, satisfactorily pure 18 in 72% yield (29 mg), mp Ͼ260°C. H, 4.03; N, 13.99. Found: C, 54.41; H, 4.31; N, 13.63 . 15-1.36 (m, 6H) , 5.72; N, 12.22. Found: C, 57.35; H, 5.59; N, 12.69 , 4.51; N, 13.92. Found: C, 53.24; H, 4.73; N, 14.03 .
Inhibition of DHFR The standard assay for DHFR activity depends on the oxidation of the cofactor NADPH, which occurs concurrently with the reduction of the substrate dihydrofolate, and is followed by a reduction in the optical density of the reaction mixture at 340 nm. The reaction mixture, in cuvettes of 1 cm path length, was made up of: 100 ml 1 mM NADPH, 50 ml 1.2 mM dihydrofolate (DHF), tested inhibitor, enzyme, and made up to 1 ml with 50 mM imidazole buffer, pH 7.0.
The amount of enzyme was adjusted to give a reduction of OD 340 of about 0.04 units per minute. The reaction was started by addition of DHF after a 3 min pre-incubation of the other components. The reaction was carried out at a temperature of 25°C. Measurements were made at various inhibitor concentrations and the IC 50 (concentration required to reduce the activity by 50%) was determined graphically.
In vitro Antibacterial Activity Bacterial strains were obtained from the F. Hoffmann-La Roche collection. MICs were routinely determined by an agar dilution method 14) using Iso-Sensitest agar (Oxoid). Stock solutions of the compounds were prepared in dimethyl sulfoxide (DMSO). Agar plates containing serial twofold dilution of the tested compounds were inoculated with the help of a multipoint inoculator (Denley A400) to yield about 1ϫ10 Ϫ4 to 5ϫ10 Ϫ4 CFU (Colonies Forming Unity) per spot. The plates were evaluated after incubation for 18 h at 37°C. The MIC was defined at the lowest concentration of a compound that prevented clearly visible growth. TMP was used as a reference compound.
In vitro Activity against Plasmodium falciparum Antimalarial activity was tested against P. falciparum according to the method described by Desjardins et al. 15) Strain K1 (resistant to chloroquine and pyrimethamine) and strain NF54 (sensitive to standard antimalarials) were used.
